An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema
Researchers are conducting a study to test a new medicine called Dupilumab, also known as Dupixent, for people suffering from nummular eczema. Nummular eczema causes coin-shaped patches of very itchy skin. This study aims to find out if Dupilumab can effectively improve the skin condition and general well-being of those affected. It's designed to be a thorough investigation, comparing Dupilumab to a dummy treatment, to clearly see its effects. The main goal is to measure how much the eczema improves over 16 weeks. They will also look at other factors like how much itching is reduced, how people's daily lives are affected, and if the treatment causes any side effects. This research is a crucial step towards potentially offering a new option for managing nummular eczema.
At a glance
What is this study about?
Imagine you have coin-shaped patches of very itchy skin – that's nummular eczema. It can be really uncomfortable and impact your daily life. This study is like a special experiment to see if a new medicine, called Dupilumab (you might hear it called Dupixent), can help people with this type of eczema. Researchers want to understand if it makes the skin patches better and reduces the itching.
In this study, some people will get the active medicine, Dupilumab, and others will get a 'dummy' treatment (a placebo) that looks just like the real medicine but has no active ingredients. Neither you nor your doctor will know which one you are receiving – this is to make sure the study results are as fair and accurate as possible. This approach helps us truly understand if Dupilumab is effective.
The main thing researchers want to find out is how much your eczema improves over 16 weeks. They'll measure this using a special scoring system for eczema. They will also look at how much your itching reduces, if your overall skin condition gets better according to your doctor, how the eczema affects your daily activities, and your general satisfaction with the treatment. Importantly, they will also closely monitor if the medicine causes any side effects to make sure it's safe.
Key takeaways
- New study exploring Dupilumab (Dupixent) for nummular eczema.
- Compares Dupilumab to a dummy treatment over 16 weeks.
- Aims to check if symptoms like itching and skin condition improve.
- Closely monitors for any side effects.
- For adults aged 18 and over, both men and women.
- Your participation is voluntary and you can withdraw anytime.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years old or older. The study is open to both men and women.
Beyond these basic requirements, the research team will have specific medical criteria to decide if the study is right for you. They will need to confirm that you have nummular eczema and that it's suitable for this particular study based on its severity and other health factors.
It's very important that you discuss your full medical history with the study doctors. They will explain all the requirements and check if you meet all the necessary criteria to ensure your safety and that the study results are meaningful.
- Are you 18 years old or older?
- Do you have nummular eczema?
- Are you able to attend regular clinic visits for 16 weeks?
- Are you willing to potentially receive either the study drug or a placebo?
- Are you comfortable with injections under the skin?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you will receive either the study medicine, Dupilumab, or a placebo (a dummy medicine) through an injection under your skin using a pre-filled syringe. You'll have regular visits to the clinic over 16 weeks so the doctors can monitor your eczema and overall health. During these visits, doctors will examine your skin, ask you questions about your symptoms like itching, and you might fill out questionnaires about how your eczema affects your daily life and your satisfaction with the treatment. There will also be assessments to check for any side effects. The total duration of the medicine part of the study is 16 weeks, with follow-up appointments after that to ensure your well-being.
Potential risks and benefits
Locations (1)
- —Germany
Common questions
What is nummular eczema?
It's a type of eczema that causes distinct coin-shaped patches of highly itchy skin.
What is Dupilumab (Dupixent)?
It's a new medicine being tested to see if it can help improve nummular eczema.
Will I know if I'm getting the real medicine or a dummy treatment?
No, neither you nor your doctor will know, to make sure the study results are unbiased.
How long does the main treatment part of the study last?
The main treatment phase of the study lasts for 16 weeks.
What happens if I want to stop participating?
You are free to leave the study at any time, for any reason, without it affecting your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.